ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v20i4.2605ppharm-2346Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWКлинико-диагностическая ценность серологических маркеров воспалительных заболеваний кишечника у детей (обзор литературы)Clinical and Diagnostic Value of Inflammatory Bowel Diseases' Serological Markers in Children (Literature Review)https://orcid.org/0000-0002-2957-680XКамаловаА. А.KamalovaAelita A.

Камалова Аэлита Асхатовна – доктор медицинских наук, профессор.

Казань

MD, PhD, Professor.

Kazan

aelitakamalova@gmail.comhttps://orcid.org/0009-0009-0814-0773ХанафинаМ. А.KhanafinaMarina A.

Ханафина Марина Алексеевна - ординатор кафедры госпитальной педиатрии.

420012, Казань, ул. Бутлерова, 49

тел.: +7 (986) 931-79-46

MD.

49 Butlerova Str., Kazan, 420012.

tel.: +7 (986) 931-79 46

marinaakhan@mail.ruhttps://orcid.org/0000-0002-4333-8779ГаринаГ. А.GarinaGalina A.

Гарина Галина Алексеевна.

Казань

MD.

Kazan

galinagalina.gala@yandex.ruКазанский государственный медицинский университет; Детская республиканская клиническая больницаРоссияKazan State Medical University; Children's Republican Clinical HospitalRussian FederationКазанский государственный медицинский университетРоссияKazan State Medical UniversityRussian Federation202322082023204309317Copyright © Камалова А.А., Ханафина М.А., Гарина Г.А., 20232023Камалова А.А., Ханафина М.А., Гарина Г.А.Kamalova A.A., Khanafina M.A., Garina G.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2346

Распространенность воспалительных заболеваний кишечника (ВЗК) растет во всем мире. Болезнь Крона (БК) и язвенный колит (ЯК) характеризуются хроническим прогредиентным течением, высокой частотой осложнений и повышенным риском оперативного вмешательства. До 50% пациентов с БК умирают от ее осложнений, а четверть пациентов нуждается как минимум в одной операции в течение жизни. У людей, страдающих ВЗК, в 8 раз выше риск колоректального рака и рака тонкой кишки. В 25% случаев диагноз ВЗК выставляется в детском возрасте. Ранняя интенсифицированная терапия отдельных групп пациентов могла бы значительно снизить частоту осложнений и хирургических вмешательств. Однако в настоящее время не существует достоверных прогностических критериев неблагоприятного течения ВЗК. Цель данного обзора — охарактеризовать наиболее изученные на данный момент серологические маркеры ВЗК и оценить вклад иммунореактивности в течение БК и ЯК у детей.

The prevalence of inflammatory bowel diseases (IBD) is increasing worldwide. Crohn's disease (CD) and ulcerative colitis (UC) are characterized by chronic progressive course, high frequency of complications, and high risk of surgical treatment. Up to 50% of CD patients die due to its complications, and quarter of these patients require at least one surgery during their lifetime. IBD patients have 8 times higher risk of colorectal and small intestine cancer. IBD diagnosis can be established during childhood in 25% of cases. Early intensified therapy of individual patient groups could significantly reduce complications and surgical treatment rates. However, nowadays there are no reliable prognostic criteria for the unfavorable course of IBD. The aim of this review is to define the most studied IBD serological markers and to evaluate immune reactivation role in CD and UC course in children.

воспалительные заболевания кишечника (ВЗК)серологические маркерыбиомаркерыдетиinflammatory bowel diseases (IBD)serological markersbiomarkerschildrenОтсутствует.Not specified.ReferencesHammer T, Langholz E. The epidemiology of inflammatory bowel disease: balance between East and West? A narrative review. Dig Med Res. 2020;3:48. doi: https://doi.org/10.21037/dmr-20-149Hammer T, Langholz E. The epidemiology of inflammatory bowel disease: balance between East and West? A narrative review. Dig Med Res. 2020;3:48. doi: https://doi.org/10.21037/dmr-20-149Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942-951. doi: https://doi.org/10.1097/MOG.0b013e32836229fbBurisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942-951. doi: https://doi.org/10.1097/MOG.0b013e32836229fbКорниенко Е.А., Хавкин А.И., Федулова Е.Н. и др. Проект рекомендаций российского общества детских гастроэнтерологов, гепатологов и нутрициологов по диагностике и лечению болезни Крона у детей // Экспериментальная и клиническая гастроэнтерология. — 2019. — № 11. — С. 100-134. — doi: https://doi.org/10.31146/1682-8658-ecg-171-11-100-134Kornienko EA, Khavkin AI, Fedulova EN, et al. Draft recommendations of the russian society of pediatric gastroenterology, hepatology and nutrition on diagnosis and treatment of Crohn's disease in children. Experimental and Clinical Gastroenterology. 2019;(11):100-134. (In Russ). doi: 10.31146/1682-8658-ecg-171-11-100-134Алхасов А.Б., Батаев С.М., Бельмер С.В. и др. Детская гастроэнтерология: национальное руководство. — М.: ГЭОТАР-Медиа; 2022. — С. 391-433. — (Национальные руководства). — doi: https://doi.org/10.33029/9704-6990-3-GAS-2022-1-864Alhasov AB, Bataev SM, Belmer SD, et al. Detskaya gastroenterologiya: National guide. Series “National guides”. Moscow: GEOTAR-Media; 2022. pp. 391-433. (In Russ). doi: https://doi.org/10.33029/9704-6990-3-GAS-2022-1-864Вахитов Т.Я., Кононова С.В., Демьянова Е.В. и др. Выявление потенциальных биомаркеров воспалительных заболеваний кишечника с помощью нецелевой метаболомики сыворотки крови // Вопросы детской диетологии. — 2022. — Т. 20. — № 6. — С. 21-32. — doi: https://doi.org/10.20953/1727-5784-2022-6-21-32Vakhitov TYa, Kononova SV, Demyanova EV, et al. Identification of candidate biomarkers for inflammatory bowel disease using non-targeted serum metabolomics. Pediatric Nutrition. 2022;20(6):21-32. (In Russ). doi: https://doi.org/10.20953/1727-5784-2022-6-21-32Ashton JJ, Versteegh HP, Batra A, et al. Colectomy in pediatric ulcerative colitis: A single center experience of indications, outcomes, and complications. J Pediatr Surg. 2016;51(2):277-281. doi: https://doi.org/10.1016/j.jpedsurg.2015.10.077Ashton JJ, Versteegh HP, Batra A, et al. Colectomy in pediatric ulcerative colitis: A single center experience of indications, outcomes, and complications. J Pediatr Surg. 2016;51(2):277-281. doi: https://doi.org/10.1016/j.jpedsurg.2015.10.077Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353-1365. doi: https://doi.org/10.1111/apt.16060Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353-1365. doi: https://doi.org/10.1111/apt.16060Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep. 2020;22(8):36. doi: https://doi.org/10.1007/s11894-020-00773-3Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep. 2020;22(8):36. doi: https://doi.org/10.1007/s11894-020-00773-3Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci. 2019;20(10):2529. doi: https://doi.org/10.3390/ijms20102529Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci. 2019;20(10):2529. doi: https://doi.org/10.3390/ijms20102529Akpunonu B, Hummell J, Akpunonu JD, Ud Din S. Capsule endoscopy in gastrointestinal disease: Evaluation, diagnosis, and treatment. Cleve Clin J Med. 2022;89(4):200-211. doi: https://doi.org/10.3390/ijms20102529Akpunonu B, Hummell J, Akpunonu JD, Ud Din S. Capsule endoscopy in gastrointestinal disease: Evaluation, diagnosis, and treatment. Cleve Clin J Med. 2022;89(4):200-211. doi: https://doi.org/10.3390/ijms20102529Ликутов А.А., Веселов В.В., Притула Н.А. и др. Возможности видеокапсульной эндоскопии в диагностике воспалительных заболеваний кишечника // Эндоскопическая хирургия. — 2017. — № 2. — С. 23-28. — doi: https://doi.org/10.17116/endoskop201723223-27Likutov AA, Veselov VV, Pritula NA, et al. Possibilities of videocapsule endoscopy in the diagnosis of inflammatory bowel diseases. Endoscopic Surgery. 2017;23(2):2327. (In Russ). doi: https://doi.org/10.17116/endoskop201723223-27Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. doi: https://doi.org/10.1093/ecco-jcc/jjy113Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. doi: https://doi.org/10.1093/ecco-jcc/jjy113Совалкин В.И., Бикбавова Г.Р., Емельянова Ю.А. Современный взгляд на патогенез и лабораторную диагностику язвенного колита (обзор литературы) // Архивъ внутренней медицины. — 2017. — Т. 7. — № 4. — C. 252-259. — doi: https://doi.org/10.20514/2226-6704-2017-7-4-252-259Sovalkin VI, Bikbavova GR, Emel'yanova YuA. The modern view of the pathogenesis and laboratory diagnostics of ulcerative colitis (literatire review). The Russian Archives of Internal Medicine. 2017;7(4):252-259. (In Russ). doi: https://doi.org/10.20514/2226-6704-2017-7-4-252-259Sakurai T, Saruta M. Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. Digestion. 2023;104(1):30-41. doi: https://doi.org/10.1159/000527846Sakurai T, Saruta M. Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. Digestion. 2023;104(1):30-41. doi: https://doi.org/10.1159/000527846Алхасов А.Б., Бехтерева М.К., Волынец Г.В. и др. Болезни кишечника у детей / под общ. ред. С.В. Бельмера, А.Ю. Разумовского, А.И. Хавкина. — М.: Медпрактика-М; 2018. — Т. 1. — 435 с.Alkhasov AB, Bekhtereva MK, Volynets GV, et al. Bolezni kishechnika u detei. Bel'mer SV, Razumovskii AYu, Khavkin AI, eds. Moscow: Medpraktika-M; 2018. Vol. 1. 435 p. (In Russ).Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6(10):1105-1111. doi: https://doi.org/10.1016/j.cgh.2008.04.032Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6(10):1105-1111. doi: https://doi.org/10.1016/j.cgh.2008.04.032Steiner CA, Berinstein JA, Louissaint J, et al. Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2022;20(4):817-846.e10. doi: https://doi.org/10.1016/j.cgh.2021.05.054Steiner CA, Berinstein JA, Louissaint J, et al. Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2022;20(4):817-846.e10. doi: https://doi.org/10.1016/j.cgh.2021.05.054Yang W, Yu T, Cong Y. Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice. J Vis Exp. 2021;(178). doi: https://doi.org/10.3791/63293Yang W, Yu T, Cong Y. Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice. J Vis Exp. 2021;(178). doi: https://doi.org/10.3791/63293Pang Y, Ruan H, Wu D, et al. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy Asthma Clin Immunol. 2020;16:37. doi: https://doi.org/10.1186/s13223-020-00433-1Pang Y, Ruan H, Wu D, et al. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy Asthma Clin Immunol. 2020;16:37. doi: https://doi.org/10.1186/s13223-020-00433-1Liu X, Guo D, Li X, et al. Value of combined detection of PCA, ANCA, ASCA, AGA and ANA in early diagnosis of Gastrointestinal Diseases. Pak J Med Sci. 2022;38(1):227-231. doi: https://doi.org/10.12669/pjms.38.1.4682Liu X, Guo D, Li X, et al. Value of combined detection of PCA, ANCA, ASCA, AGA and ANA in early diagnosis of Gastrointestinal Diseases. Pak J Med Sci. 2022;38(1):227-231. doi: https://doi.org/10.12669/pjms.38.1.4682Iltanen S, Tervo L, Halttunen T, et al. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm Bowel Dis. 2006;12(5):389-394. doi: https://doi.org/10.1097/01.MIB.0000218765.84087.42Iltanen S, Tervo L, Halttunen T, et al. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm Bowel Dis. 2006;12(5):389-394. doi: https://doi.org/10.1097/01.MIB.0000218765.84087.42Wang H, Demirkan G, Bian X, et al. Identification of Antibody Against SNRPB, Small Nuclear Ribonucleoprotein-Associated Proteins B and B‘, as an Autoantibody Marker in Crohn's Disease using an Immunoproteomics Approach. J Crohns Colitis. 2017;11(7):848-856. doi: https://doi.org/10.1093/ecco-jcc/jjx019Wang H, Demirkan G, Bian X, et al. Identification of Antibody Against SNRPB, Small Nuclear Ribonucleoprotein-Associated Proteins B and B‘, as an Autoantibody Marker in Crohn's Disease using an Immunoproteomics Approach. J Crohns Colitis. 2017;11(7):848-856. doi: https://doi.org/10.1093/ecco-jcc/jjx019Kovacs M, Lakatos PL, Papp M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012;55(4):429-435. doi: https://doi.org/10.1097/MPG.0b013e318256b516Kovacs M, Lakatos PL, Papp M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012;55(4):429-435. doi: https://doi.org/10.1097/MPG.0b013e318256b516Hanzel J, Ma C, Casteele NV, et al. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs. 2021;81(3):333-347. doi: https://doi.org/10.1007/s40265-020-01460-3Hanzel J, Ma C, Casteele NV, et al. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs. 2021;81(3):333-347. doi: https://doi.org/10.1007/s40265-020-01460-3Rieder F, Hahn P, Finsterhoelzl L, et al. Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort. Inflamm Bowel Dis. 2012;18(7):1221-1231. doi: https://doi.org/10.1002/ibd.21854Rieder F, Hahn P, Finsterhoelzl L, et al. Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort. Inflamm Bowel Dis. 2012;18(7):1221-1231. doi: https://doi.org/10.1002/ibd.21854Tian Y, Wang HH. The application value of serological detection of ASCA and ANCA serum level in the diagnosis and treatment of inflammatory bowel disease. Chinese J Lab Med. 2018;41(10):708-711. doi: https://doi.org/10.3760/cma.j.issn.1009-9158.2018.10.002Tian Y, Wang HH. The application value of serological detection of ASCA and ANCA serum level in the diagnosis and treatment of inflammatory bowel disease. Chinese J Lab Med. 2018;41(10):708-711. doi: https://doi.org/10.3760/cma.j.issn.1009-9158.2018.10.002Mitsuyama K, Niwa M, Takedatsu H, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304-1310. doi: https://doi.org/10.3748/wjg.v22.i3.1304Mitsuyama K, Niwa M, Takedatsu H, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304-1310. doi: https://doi.org/10.3748/wjg.v22.i3.1304Александрова Е.Н., Новиков А.А., Лукина Г.В., Парфенов А.И. Клиническое значение антител при воспалительных заболеваниях кишечника // Терапевтический архив. — 2021. — Т. 93. — № 2. — С. 228-235. — doi: https://doi.org/10.26442/00403660.2021.02.200610Aleksandrova EN, Novikov AA, Lukina GV, Parfenov AI. Clinical value of antibodies in inflammatory bowel diseases. Terapevticheskii Arkhiv. 2021;93(2):228-235 (In Russ). doi: https://doi.org/10.26442/00403660.2021.02.200610Кузнецова Д.А., Лапин С.В., Щукина О.Б. Диагностическая и прогностическая значимость серологических маркеров воспалительных заболеваний кишечника (обзор литературы) // Альманах клинической медицины. — 2020. — Т. 48. — № 6. — C. 364-374. — doi: https://doi.org/10.18786/2072-0505-2020-48-061Kuznetsova DA, Lapin SV, Shchukina OB. The diagnostic and prognostic value of serological markers of inflammatory bowel diseases (a literature review). Almanac of Clinical Medicine. 2020;48(6):364-374. (In Russ). doi: https://doi.org/10.18786/2072-0505-2020-48-061Hashash JG, Koutroumpakis F, Anderson AM, et al. Elevated serum globulin fraction as a biomarker of multiyear disease severity in inflammatory bowel disease. Ann Gastroenterol. 2022;35(6):609-617. doi: https://doi.org/10.20524/aog.2022.0748Hashash JG, Koutroumpakis F, Anderson AM, et al. Elevated serum globulin fraction as a biomarker of multiyear disease severity in inflammatory bowel disease. Ann Gastroenterol. 2022;35(6):609-617. doi: https://doi.org/10.20524/aog.2022.0748Chen P, Zhou G, Lin J, et al. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:123. doi: https://doi.org/10.3389/fmed.2020.00123Chen P, Zhou G, Lin J, et al. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:123. doi: https://doi.org/10.3389/fmed.2020.00123Smids C, Horjus Talabur Horje CS, Groenen MJM, et al. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017;52(10):1104-1112. doi: https://doi.org/10.1080/00365521.2017.1344875Smids C, Horjus Talabur Horje CS, Groenen MJM, et al. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017;52(10):1104-1112. doi: https://doi.org/10.1080/00365521.2017.1344875Быков А.С., Караулов А.В., Цомартова Д.А. и др. М-клетки — один из важных компонентов в инициации иммунного ответа в кишечнике // Инфекция и иммунитет. — 2018. — Т. 8. — № 3. — C. 263-272. — doi: https://doi.org/10.15789/2220-7619-2018-3-263-272Bykov AS, Karaulov AV, Tsomartova DA, et al. M cells are the important post in the initiation of immune response in intestine. Russian Journal of Infection and Immunity. 2018;8(3):263-272. (In Russ). doi: https://doi.org/10.15789/2220-7619-2018-3-263-272Shpoliansky M, Roggenbuck D, Pinsker M, et al. Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease. Dig Dis Sci. 2021;66(8):2619-2626. doi: https://doi.org/10.1007/s10620-020-06589-5Shpoliansky M, Roggenbuck D, Pinsker M, et al. Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease. Dig Dis Sci. 2021;66(8):2619-2626. doi: https://doi.org/10.1007/s10620-020-06589-5Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an Anti-Integrin ave6 Autoantibody in Patients With Ulcerative Colitis. Gastroenterology. 2021;160(70):2383-2394.e21. doi: https://doi.org/10.1053/j.gastro.2021.02.019Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an Anti-Integrin ave6 Autoantibody in Patients With Ulcerative Colitis. Gastroenterology. 2021;160(70):2383-2394.e21. doi: https://doi.org/10.1053/j.gastro.2021.02.019Venkateswaran S, Denson LA, Jurickova I, et al. Neutrophil GM-CSF signaling in inflammatory bowel disease patients is influenced by non-coding genetic variants. Sci Rep. 2019;9(1):9168. doi: https://doi.org/10.1038/s41598-019-45701-2Venkateswaran S, Denson LA, Jurickova I, et al. Neutrophil GM-CSF signaling in inflammatory bowel disease patients is influenced by non-coding genetic variants. Sci Rep. 2019;9(1):9168. doi: https://doi.org/10.1038/s41598-019-45701-2Зурочка А.В., Зурочка В.А., Добрынина М.А., Гриценко В.А. Иммунобиологические свойства гранулоцитарно-макрофагального колониестимулирующего фактора и синтетических пептидов его активного центра // Медицинская иммунология. — 2021. — Т. 23. — № 5. — С. 1031-1054. — doi: https://doi.org/10.15789/1563-0625-IPO-2216Zurochka AV, Zurochka VA, Dobrynina MA, Gritsenko VA. Immunobiological properties of granulocytemacrophage colony-stimulating factor and synthetic peptides of his active center. Medical Immunology (Russia). 2021;23(5):1031-1054. (In Russ). doi: https://doi.org/10.15789/1563-0625-IPO-2216Duryee MJ, Ahmad R, Eichele DD, et al. Identification of Immunoglobulin G Autoantibody Against MalondialdehydeAcetaldehyde Adducts as a Novel Serological Biomarker for Ulcerative Colitis. Clin Transl Gastroenterol. 2022;13(4):e00469. doi: https://doi.org/10.14309/ctg.0000000000000469Duryee MJ, Ahmad R, Eichele DD, et al. Identification of Immunoglobulin G Autoantibody Against MalondialdehydeAcetaldehyde Adducts as a Novel Serological Biomarker for Ulcerative Colitis. Clin Transl Gastroenterol. 2022;13(4):e00469. doi: https://doi.org/10.14309/ctg.0000000000000469Kovacs M, Muller KE, Papp M, et al. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol. 2014;20(17):4873-4882. doi: https://doi.org/10.3748/wjg.v20.i17.4873Kovacs M, Muller KE, Papp M, et al. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol. 2014;20(17):4873-4882. doi: https://doi.org/10.3748/wjg.v20.i17.4873Ricciuto A, Aardoom M, Orlanski-Meyer E, et al. Predicting Outcomes in Pediatric Crohn's Disease for Management Optimization: Systematic Review and Consensus Statements From the Pediatric Inflammatory Bowel Disease-Ahead Program. Gastroenterology. 2021;160(1):403-436. doi: https://doi.org/10.1053/j.gas-tro.2020.07.065Ricciuto A, Aardoom M, Orlanski-Meyer E, et al. Predicting Outcomes in Pediatric Crohn's Disease for Management Optimization: Systematic Review and Consensus Statements From the Pediatric Inflammatory Bowel Disease-Ahead Program. Gastroenterology. 2021;160(1):403-436. doi: https://doi.org/10.1053/j.gas-tro.2020.07.065Abu-Freha N, Badarna W, Sigal-Batikoff I, et al. ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation. BMC Gastroenterol. 2018;18(1):153. doi: https://doi.org/10.1186/s12876-018-0884-xAbu-Freha N, Badarna W, Sigal-Batikoff I, et al. ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation. BMC Gastroenterol. 2018;18(1):153. doi: https://doi.org/10.1186/s12876-018-0884-xLi BH, Guan X, Vittinghoff E, Gupta N. Comparison of the presentation and course of pediatric inflammatory bowel disease in South Asians with Whites: a single center study in the United States. J Pediatr. 2013;163(4):1211-1213. doi: https://doi.org/10.1016/j.jpeds.2013.04.017Li BH, Guan X, Vittinghoff E, Gupta N. Comparison of the presentation and course of pediatric inflammatory bowel disease in South Asians with Whites: a single center study in the United States. J Pediatr. 2013;163(4):1211-1213. doi: https://doi.org/10.1016/j.jpeds.2013.04.017Duarte-Silva M, Afonso PC, de Souza PR, et al. Reappraisal of antibodies against Saccharomyces cerevisiae (ASCA) as persistent biomarkers in quiescent Crohn's disease. Autoimmunity. 2019;52(1):37-47. doi: https://doi.org/10.1080/08916934.2019.1588889Duarte-Silva M, Afonso PC, de Souza PR, et al. Reappraisal of antibodies against Saccharomyces cerevisiae (ASCA) as persistent biomarkers in quiescent Crohn's disease. Autoimmunity. 2019;52(1):37-47. doi: https://doi.org/10.1080/08916934.2019.1588889Yorulmaz E, Adali G, Yorulmaz H, et al. The Correlation between New Serological Markers and Disease Phenotype and Activation in Inflammatory Bowel Disease. Middle East J Dig Dis. 2022;14(3):294-303. doi: https://doi.org/10.34172/mejdd.2022.286Yorulmaz E, Adali G, Yorulmaz H, et al. The Correlation between New Serological Markers and Disease Phenotype and Activation in Inflammatory Bowel Disease. Middle East J Dig Dis. 2022;14(3):294-303. doi: https://doi.org/10.34172/mejdd.2022.286Chandrakumar A, Georgy M, Agarwal P, et al. Anti-Saccharomyces cerevisiae Antibodies as a Prognostic Biomarker in Children With Crohn Disease. J Pediatr Gastroenterol Nutr. 2019;69(1):82-87. doi: https://doi.org/10.1097/MPG.0000000000002311Chandrakumar A, Georgy M, Agarwal P, et al. Anti-Saccharomyces cerevisiae Antibodies as a Prognostic Biomarker in Children With Crohn Disease. J Pediatr Gastroenterol Nutr. 2019;69(1):82-87. doi: https://doi.org/10.1097/MPG.0000000000002311Olbj0rn C, Cvancarova Smastuen M, Thiis-Evensen E, et al. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol. 2017;52(4):414-419. doi: https://doi.org/10.1080/00365521.2016.1259653Olbj0rn C, Cvancarova Smastuen M, Thiis-Evensen E, et al. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol. 2017;52(4):414-419. doi: https://doi.org/10.1080/00365521.2016.1259653Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet. 2017;389(10080):1710-1718. doi: https://doi.org/10.1016/S0140-6736(17)30317-3Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet. 2017;389(10080):1710-1718. doi: https://doi.org/10.1016/S0140-6736(17)30317-3Torres J, Petralia F, Sato T, et al. Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology. 2020;159(1):96-104. doi: https://doi.org/10.1053/j.gastro.2020.03.007Torres J, Petralia F, Sato T, et al. Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology. 2020;159(1):96-104. doi: https://doi.org/10.1053/j.gastro.2020.03.007Dykes DM, Towbin AJ, Bonkowski E, et al. Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocytemacrophage colony stimulating factor autoantibodies. Inflamm Bowel Dis. 2013;19(10):2146-2154. doi: https://doi.org/10.1097/MIB.0b013e31829706e0Dykes DM, Towbin AJ, Bonkowski E, et al. Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocytemacrophage colony stimulating factor autoantibodies. Inflamm Bowel Dis. 2013;19(10):2146-2154. doi: https://doi.org/10.1097/MIB.0b013e31829706e0Kristensen VA, Cvancarova M, H0ivik ML, et al. Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients — the IBSEN study. Scand J Gastroenterol. 2020;55(4):436-441. doi: https://doi.org/10.1080/00365521.2020.1745879Kristensen VA, Cvancarova M, H0ivik ML, et al. Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients — the IBSEN study. Scand J Gastroenterol. 2020;55(4):436-441. doi: https://doi.org/10.1080/00365521.2020.1745879

The authors declare that there are no conflicts of interest present.